ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Is Down 15.9% After Reaffirming 2025 Revenue Outlook and Increased R&D Spend
On July 22, 2025, Telix Pharmaceuticals confirmed its revenue guidance for fiscal year 2025 at A$770 million to A$800 million, driven by ongoing Illuccix sales and 11 months of contributions from its RLS acquisition, while also projecting a 20% to 25% increase in R&D expenditures over the previous year.
This reaffirmed outlook highlights Telix's focus on balancing robust commercial operations with sizable investment in future research initiatives.
We’ll explore how Telix’s increased R&D...